- Home
- NTRA vs XYL Comparison
NTRA vs XYL Comparison
Compare NTRA & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRA | XYL |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 36.7B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRA | XYL |
|---|---|---|
| Price | $231.21 | $138.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 10 |
| Target Price | ★ $249.53 | $161.78 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 1.16% |
| EPS Growth | N/A | ★ 13.52 |
| EPS | N/A | ★ 3.88 |
| Revenue | $2,116,676,000.00 | ★ $8,894,000,000.00 |
| Revenue This Year | $33.77 | $6.51 |
| Revenue Next Year | $16.92 | $3.37 |
| P/E Ratio | ★ N/A | $35.55 |
| Revenue Growth | ★ 38.17 | 5.58 |
| 52 Week Low | $125.38 | $100.48 |
| 52 Week High | $256.36 | $154.27 |
Technical Indicators
Market Signals| Indicator | NTRA | XYL |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 46.20 |
| Support Level | $229.14 | $132.36 |
| Resistance Level | $250.00 | $143.86 |
| Average True Range (ATR) | 8.27 | 3.15 |
| MACD | -1.38 | -0.44 |
| Stochastic Oscillator | 21.29 | 40.55 |
Price Performance
Historical ComparisonAbout NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.